Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
American Journal of Clinical Dermatology
Published in: American Journal of Clinical Dermatology 4/2000

01-07-2000 | Adis New Drug Profile

Bexarotene

A Viewpoint by Ann G. Martin

Author: Ann G. Martin

Published in: American Journal of Clinical Dermatology | Issue 4/2000

Login to get access

Excerpt

The focus of contemporary cutaneous T cell lymphoma (CTCL) management is to achieve therapy-induced remissions at all stages of disease. Bexarotene is a novel retinoid agent that has demonstrated substantial clinical activity against CTCL.[1‐4] However, its precise mechanism of action in this disease remains to be elucidated. Bexarotene is known to produce alterations in cellular growth, proliferation, differentiation and apoptosis through selective retinoid X receptor activation; this unique activity as a ‘rexinoid’ may account for its potential lack of cross-resistance and overlapping toxicity with currently available CTCL therapies. …
Literature
1.
Duvic M., Hymes K., Heald P., et al. Phase II–III clinical trial of bexarotene capsules in patients with refractory advanced stage CTCL demonstrates efficacy and safety [abstract no. 60 & poster]. American Academy of Dermatology 58th Annual Meeting; 2000 Mar 10–15; San Francisco
2.
Duvic M., Martin A., Kim Y., et al. Phase II–III clinical trial of bexarotene capsules demonstrates efficacy and safety for patients with refractory or persistent early stage CTCL [abstract no. 231 & poster]. American Academy of Dermatology 58th Annual Meeting; 2000 Mar 10–15; San Francisco
3.
Heald P., Mehlmauer M., Martin A., et al. The benefits of topical bexarotene (Targretin ®) in patients with refractory or persistent early stage CTCL [abstract no. 545]. J Invest Dermatol 2000, 114: 840
4.
Kuzel T., Breneman D., Duvic M., et al. Phase I–II trial of Targretin® gel in the topical treatment of patients with cutaneous T-cell lymphoma [abstract no. 536]. J Invest Dermatol 2000; 114: 839
5.
Ligand Pharmaceuticals Targretin® (bexarotene) capsules, 75mg prescribing information. San Diego, California, USA, December 1999
Metadata
Title
Bexarotene
A Viewpoint by Ann G. Martin
Author
Ann G. Martin
Publication date
01-07-2000
Publisher
Springer International Publishing
Published in
American Journal of Clinical Dermatology / Issue 4/2000
Print ISSN: 1175-0561
Electronic ISSN: 1179-1888
DOI
https://doi.org/10.2165/00128071-200001040-00008

Other articles of this Issue 4/2000

American Journal of Clinical Dermatology 4/2000 Go to the issue

Pharmacovigilance

Drug Reaction Case Reports

Adis New Drug Profile

Bexarotene

Review Article

Antineoplastic Therapy—Induced Palmar Plantar Erythrodysesthesia (‘Hand-Foot’) Syndrome

Leading Article

Assessment and Clinical Implications of Absorption of Sunscreens Across Skin

Review Article

Body Dysmorphic Disorder

Adis New Drug Profile

Bexarotene